Logo image of NUVB

NUVATION BIO INC (NUVB) Stock Fundamental Analysis

USA - New York Stock Exchange - NYSE:NUVB - US67080N1019 - Common Stock

8.43 USD
+0.16 (+1.93%)
Last: 12/12/2025, 8:04:00 PM
8.36 USD
-0.07 (-0.83%)
After Hours: 12/12/2025, 8:04:00 PM
Fundamental Rating

2

Taking everything into account, NUVB scores 2 out of 10 in our fundamental rating. NUVB was compared to 191 industry peers in the Pharmaceuticals industry. While NUVB seems to be doing ok healthwise, there are quite some concerns on its profitability. NUVB is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

NUVB had negative earnings in the past year.
NUVB had a negative operating cash flow in the past year.
In the past 5 years NUVB always reported negative net income.
NUVB had a negative operating cash flow in each of the past 5 years.
NUVB Yearly Net Income VS EBIT VS OCF VS FCFNUVB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M -400M -500M

1.2 Ratios

With a Return On Assets value of -36.15%, NUVB perfoms like the industry average, outperforming 45.55% of the companies in the same industry.
NUVB has a Return On Equity (-66.74%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -36.15%
ROE -66.74%
ROIC N/A
ROA(3y)-44.25%
ROA(5y)-34.58%
ROE(3y)-50.3%
ROE(5y)-38.48%
ROIC(3y)N/A
ROIC(5y)N/A
NUVB Yearly ROA, ROE, ROICNUVB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400

1.3 Margins

NUVB has a better Gross Margin (54.26%) than 66.49% of its industry peers.
The Profit Margin and Operating Margin are not available for NUVB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 54.26%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NUVB Yearly Profit, Operating, Gross MarginsNUVB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

4

2. Health

2.1 Basic Checks

NUVB does not have a ROIC to compare to the WACC, probably because it is not profitable.
NUVB has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, NUVB has more shares outstanding
Compared to 1 year ago, NUVB has a worse debt to assets ratio.
NUVB Yearly Shares OutstandingNUVB Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
NUVB Yearly Total Debt VS Total AssetsNUVB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

NUVB has an Altman-Z score of 3.44. This indicates that NUVB is financially healthy and has little risk of bankruptcy at the moment.
NUVB has a better Altman-Z score (3.44) than 69.63% of its industry peers.
A Debt/Equity ratio of 0.61 indicates that NUVB is somewhat dependend on debt financing.
NUVB has a worse Debt to Equity ratio (0.61) than 66.49% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.61
Debt/FCF N/A
Altman-Z 3.44
ROIC/WACCN/A
WACC9.24%
NUVB Yearly LT Debt VS Equity VS FCFNUVB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

NUVB has a Current Ratio of 8.48. This indicates that NUVB is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 8.48, NUVB is in the better half of the industry, outperforming 74.87% of the companies in the same industry.
NUVB has a Quick Ratio of 8.39. This indicates that NUVB is financially healthy and has no problem in meeting its short term obligations.
NUVB's Quick ratio of 8.39 is fine compared to the rest of the industry. NUVB outperforms 75.39% of its industry peers.
Industry RankSector Rank
Current Ratio 8.48
Quick Ratio 8.39
NUVB Yearly Current Assets VS Current LiabilitesNUVB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

NUVB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -48.84%.
The Revenue has grown by 1137.19% in the past year. This is a very strong growth!
EPS 1Y (TTM)-48.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.67%
Revenue 1Y (TTM)1137.19%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%1704.68%

3.2 Future

NUVB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 53.75% yearly.
Based on estimates for the next years, NUVB will show a very strong growth in Revenue. The Revenue will grow by 202.28% on average per year.
EPS Next Y-16.28%
EPS Next 2Y-0.31%
EPS Next 3Y15.7%
EPS Next 5Y53.75%
Revenue Next Year2424.31%
Revenue Next 2Y767.19%
Revenue Next 3Y406.27%
Revenue Next 5Y202.28%

3.3 Evolution

NUVB Yearly Revenue VS EstimatesNUVB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
NUVB Yearly EPS VS EstimatesNUVB Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 -2 3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NUVB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NUVB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NUVB Price Earnings VS Forward Price EarningsNUVB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NUVB Per share dataNUVB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

A more expensive valuation may be justified as NUVB's earnings are expected to grow with 15.70% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.31%
EPS Next 3Y15.7%

More info and screens

0

5. Dividend

5.1 Amount

NUVB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NUVATION BIO INC

NYSE:NUVB (12/12/2025, 8:04:00 PM)

After market: 8.36 -0.07 (-0.83%)

8.43

+0.16 (+1.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-03 2025-11-03/amc
Earnings (Next)03-04 2026-03-04/amc
Inst Owners65.09%
Inst Owner Change-2.27%
Ins Owners17.92%
Ins Owner Change0.45%
Market Cap2.89B
Revenue(TTM)26.75M
Net Income(TTM)-217.48M
Analysts83.75
Price Target10.65 (26.33%)
Short Float %24.15%
Short Ratio7.24
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.93%
Min EPS beat(2)0.88%
Max EPS beat(2)6.98%
EPS beat(4)3
Avg EPS beat(4)0.55%
Min EPS beat(4)-6.56%
Max EPS beat(4)6.98%
EPS beat(8)5
Avg EPS beat(8)-11.26%
EPS beat(12)9
Avg EPS beat(12)-2.73%
EPS beat(16)12
Avg EPS beat(16)-0.14%
Revenue beat(2)2
Avg Revenue beat(2)660.6%
Min Revenue beat(2)94.49%
Max Revenue beat(2)1226.72%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)19.85%
PT rev (3m)39.26%
EPS NQ rev (1m)-2.11%
EPS NQ rev (3m)29.93%
EPS NY rev (1m)9.27%
EPS NY rev (3m)8.5%
Revenue NQ rev (1m)10.38%
Revenue NQ rev (3m)83.66%
Revenue NY rev (1m)85.18%
Revenue NY rev (3m)63.95%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 108.05
P/FCF N/A
P/OCF N/A
P/B 8.87
P/tB 9.2
EV/EBITDA N/A
EPS(TTM)-0.64
EYN/A
EPS(NY)-0.52
Fwd EYN/A
FCF(TTM)-0.58
FCFYN/A
OCF(TTM)-0.55
OCFYN/A
SpS0.08
BVpS0.95
TBVpS0.92
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -36.15%
ROE -66.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 54.26%
FCFM N/A
ROA(3y)-44.25%
ROA(5y)-34.58%
ROE(3y)-50.3%
ROE(5y)-38.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0.61
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 581.54%
Cap/Sales 30.85%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.48
Quick Ratio 8.39
Altman-Z 3.44
F-Score4
WACC9.24%
ROIC/WACCN/A
Cap/Depr(3y)79.93%
Cap/Depr(5y)109.07%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-48.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.67%
EPS Next Y-16.28%
EPS Next 2Y-0.31%
EPS Next 3Y15.7%
EPS Next 5Y53.75%
Revenue 1Y (TTM)1137.19%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%1704.68%
Revenue Next Year2424.31%
Revenue Next 2Y767.19%
Revenue Next 3Y406.27%
Revenue Next 5Y202.28%
EBIT growth 1Y-73.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-186.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-174.8%
OCF growth 3YN/A
OCF growth 5YN/A

NUVATION BIO INC / NUVB FAQ

What is the ChartMill fundamental rating of NUVATION BIO INC (NUVB) stock?

ChartMill assigns a fundamental rating of 2 / 10 to NUVB.


What is the valuation status for NUVB stock?

ChartMill assigns a valuation rating of 0 / 10 to NUVATION BIO INC (NUVB). This can be considered as Overvalued.


How profitable is NUVATION BIO INC (NUVB) stock?

NUVATION BIO INC (NUVB) has a profitability rating of 1 / 10.


What is the expected EPS growth for NUVATION BIO INC (NUVB) stock?

The Earnings per Share (EPS) of NUVATION BIO INC (NUVB) is expected to decline by -16.28% in the next year.